Physicians' Academy for Cardiovascular Education

MTP inhibition

Slides (presentation) - Mar. 24, 2011

New Approaches to LDL Reduction
MTPIs – Efficacy comes from its dual mechanism of action
AEGR 733 HoFH Phase II Study Design
Change in Lipids Using Lomitapide with no Background Therapy
AEGR 733 HoFH Phase 3 Study Design (Ongoing)
HoFH Phase 3: 6-Month Lipid Efficacy
AEGR-733 Low Dose Development Program
Ezetimibe Combination Study: Mean LDL-C Efficacy
Impact of Low Dose MTPi on Hepatic Fat Levels (Mean Values at Week 12)
Summary of Adverse Event Experience with AEGR-733

Share this page with your colleagues and friends: